This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

Zimmer Bolts on Biomet for $13.4B

NEW YORK (The Deal) -- Zimmer Holdings (ZMH - Get Report) on Thursday said it would acquire private equity-owned Biomet in a $13.35 billion cash and stock deal that would expand the maker of artificial joints into new orthopedic devices.

Terms of the deal call for Warsaw, Ind.-based Zimmer to pay $10.35 billion in cash and also issue $3 billion worth of its shares to Biomet owners, leaving Zimmer shareholders in control of about 84% of the combination post-deal.

Biomet is currently owned by a consortium including Blackstone (BX - Get Report), TPG Capital, Kohlberg Kravis Roberts & Co. and Goldman Sachs (GS - Get Report), which acquired it in 2007 for $11.3 billion.

As part of the deal Biomet is withdrawing a planned initial public offering.

Biomet is a maker of surgical and non-surgical products used by orthopedic surgeons and other musculoskeletal specialists, including hip and knee reconstructive products, sports medicine and trauma products and spine and dental products.

Zimmer said the deal would create a leader in what it says is a $45 billion musculoskeletal surgery industry, with a more diverse portfolio and increasing cash flow compared to the company as a standalone. The combination would have pro forma annual Ebitda of about $2.8 billion on sales of $7.8 billion, with Zimmer also pledging upwards of $270 million in net annual synergies by year three.

"We believe that current demographic and macroeconomic trends affecting the healthcare industry will reward companies that successfully partner with other key stakeholders to improve patient care in a cost-effective manner," Zimmer CEO David Dvorak said in a statement. "Together with Biomet we will expand the scope of our innovation programs and will enhance our efforts to provide integrated services and comprehensive solutions that address the needs of our customers."

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
ZMH $120.39 0.00%
AGN $232.74 0.00%
BX $37.46 0.00%
GS $189.79 0.00%
VRX $197.48 0.00%


DOW 18,132.70 -81.72 -0.45%
S&P 500 2,104.50 -6.24 -0.30%
NASDAQ 4,963.5270 -24.3630 -0.49%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs